Pru p 7 sensitization is a predominant cause of severe, cypress pollen-associated peach allergy.


Journal

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443

Informations de publication

Date de publication:
04 2019
Historique:
received: 23 06 2018
revised: 11 11 2018
accepted: 12 12 2018
pubmed: 24 1 2019
medline: 10 6 2020
entrez: 24 1 2019
Statut: ppublish

Résumé

Peach is a common elicitor of food allergic reactions. Peach-induced immediate reactions may occur as benign pollen-food syndromes, usually due to birch pollen-related PR-10 cross-reactivity in temperate climates, and as potentially severe primary food allergies, predominantly related to nsLTP Pru p 3 in Mediterranean regions. The newly described peach allergen Pru p 7 has gained recent attention as a potential peach allergy severity marker. Sensitization to Pru p 7 and its allergenic homologues of the gibberellin-regulated protein family occurs in areas with high Cupressaceae tree pollen exposure. We sought to investigate the distribution, clinical characteristics and molecular associations of Pru p 7 sensitization among subjects with suspected peach allergy in different regions of France. Subjects with suspected peach allergy (n = 316) were included. Diagnostic work-up was performed according to current guidelines, including open food challenge when required. IgE antibody measurements and competition experiments were performed using the ImmunoCAP assay platform. Sensitization to Pru p 7 was present in 171 (54%) of all subjects in the study and in 123 of 198 (62%) diagnosed as peach allergic, more than half of whom were sensitized to no other peach allergen. Frequency and magnitude of Pru p 7 sensitization were associated with the presence of peach allergy, the clinical severity of peach-induced allergic reactions and the level of cypress pollen exposure. Cypress pollen extract completely outcompeted IgE binding to Pru p 7. Pru p 7 was extremely potent in basophil activation tests. A subtype of Cupressaceae pollinosis, characterized by Pru p 7 sensitization, can be an underlying cause of severe peach allergy.

Sections du résumé

BACKGROUND
Peach is a common elicitor of food allergic reactions. Peach-induced immediate reactions may occur as benign pollen-food syndromes, usually due to birch pollen-related PR-10 cross-reactivity in temperate climates, and as potentially severe primary food allergies, predominantly related to nsLTP Pru p 3 in Mediterranean regions. The newly described peach allergen Pru p 7 has gained recent attention as a potential peach allergy severity marker. Sensitization to Pru p 7 and its allergenic homologues of the gibberellin-regulated protein family occurs in areas with high Cupressaceae tree pollen exposure.
OBJECTIVE
We sought to investigate the distribution, clinical characteristics and molecular associations of Pru p 7 sensitization among subjects with suspected peach allergy in different regions of France.
METHODS
Subjects with suspected peach allergy (n = 316) were included. Diagnostic work-up was performed according to current guidelines, including open food challenge when required. IgE antibody measurements and competition experiments were performed using the ImmunoCAP assay platform.
RESULTS
Sensitization to Pru p 7 was present in 171 (54%) of all subjects in the study and in 123 of 198 (62%) diagnosed as peach allergic, more than half of whom were sensitized to no other peach allergen. Frequency and magnitude of Pru p 7 sensitization were associated with the presence of peach allergy, the clinical severity of peach-induced allergic reactions and the level of cypress pollen exposure. Cypress pollen extract completely outcompeted IgE binding to Pru p 7. Pru p 7 was extremely potent in basophil activation tests.
CONCLUSION AND CLINICAL RELEVANCE
A subtype of Cupressaceae pollinosis, characterized by Pru p 7 sensitization, can be an underlying cause of severe peach allergy.

Identifiants

pubmed: 30672059
doi: 10.1111/cea.13345
doi:

Substances chimiques

Allergens 0
Antigens, Plant 0
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

526-536

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Caroline Klingebiel (C)

Laboratoire Synlab Provence, Marseille, France.

Yannick Chantran (Y)

UPMC Univ Paris 06, INSERM UMRS 938, Centre de Recherche Saint-Antoine, team "Immune System, Neuroinflammation and Neurodegenerative Diseases", Hôpital Saint-Antoine, Sorbonne Universités, Paris, France.
Immunology Department, AP-HP Saint-Antoine Hospital, Paris, France.

Rihane Arif-Lusson (R)

Aix-Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France.

Angelica E Ehrenberg (AE)

Thermo Fisher Scientific, Uppsala, Sweden.

Jonas Östling (J)

Thermo Fisher Scientific, Uppsala, Sweden.

Alain Poisson (A)

Service de Pneumo-Allergologie, Hôpital Saint Joseph, Marseille, France.

Valérie Liabeuf (V)

Aix-Marseille Univ, APHM, Hôpital Timone, Service de Dermatologie-Vénéréologie, Marseille, France.

Chantal Agabriel (C)

Aix-Marseille Univ, APHM, Hôpital Timone, Service de Pédiatrie Multidisciplinaire, Marseille, France.

Joëlle Birnbaum (J)

Service de Pneumologie et Allergologie, CH du Pays d'Aix, Aix-en-Provence, France.

Françoise Porri (F)

Service de Pneumo-Allergologie, Hôpital Saint Joseph, Marseille, France.

Anne Sarrat (A)

Laboratoire d'Immunologie et Immunogénétique, GH Pellegrin, CHU Bordeaux, Bordeaux, France.

Pol-André Apoil (PA)

Institut Fédératif de Biologie, Hôpital Purpan, CHU Toulouse, Toulouse, France.

Mylène Vivinus (M)

Laboratoire d'Immunologie, Hôpital de l'Archet, CHU Nice, Nice, France.

Lorna Garnier (L)

Laboratoire d'Immunologie, CH Lyon Sud, CHU Lyon, Pierre-Bénite, France.

Anca Mirela Chiriac (AM)

Département de pneumologie et addictologie, CHU Montpellier, Hôpital Arnaud-de-Villeneuve, Univ Montpellier, Montpellier, France.
Sorbonne Universités, INSERM UMRS 1136, IPLESP, team EPAR, Paris, France.

Davide-Paolo Caimmi (DP)

Département de pneumologie et addictologie, CHU Montpellier, Hôpital Arnaud-de-Villeneuve, Univ Montpellier, Montpellier, France.
Sorbonne Universités, INSERM UMRS 1136, IPLESP, team EPAR, Paris, France.

Jean-Luc Bourrain (JL)

Département de pneumologie et addictologie, CHU Montpellier, Hôpital Arnaud-de-Villeneuve, Univ Montpellier, Montpellier, France.

Pascal Demoly (P)

Département de pneumologie et addictologie, CHU Montpellier, Hôpital Arnaud-de-Villeneuve, Univ Montpellier, Montpellier, France.
Sorbonne Universités, INSERM UMRS 1136, IPLESP, team EPAR, Paris, France.

Stéphane Guez (S)

Unité d'allergologie, GH Pellegrin, CHU Bordeaux, Bordeaux, France.

Franck Boralevi (F)

Unité de Dermatologie Pédiatrique, Hôpital Pellegrin-Enfants, CHU Bordeaux, Bordeaux, France.

Bertrand Lovato (B)

Medical Office, Mérignac, France.

Céline Palussière (C)

Medical Office, Cenon, France.

Sylvie Leroy (S)

Service de Pneumologie, Hôpital Pasteur, CHU Nice, Nice, France.

Thierry Bourrier (T)

Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France.

Lisa Giovannini-Chami (L)

Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France.

Marion Gouitaa (M)

Aix-Marseille Univ, APHM, Hôpital Nord, Service de Pneumologie, Marseille, France.

Agnès Aferiat-Derome (A)

Medical Office, Les Jardins de Castellane, Marseille, France.

Denis Charpin (D)

Aix-Marseille Univ, APHM, Hôpital Timone, Unité de Pneumologie, Marseille, France.

Tünde Sofalvi (T)

Aix-Marseille Univ, APHM, Hôpital Nord, Service de Pneumologie, Marseille, France.

Isabelle Cabon-Boudard (I)

Aix-Marseille Univ, APHM, Hôpital Timone, Service de Chirurgie Pédiatrique, Marseille, France.

Yann-Patrick Massabie-Bouchat (YP)

Medical Office, Marseille, France.

Bernard Hofmann (B)

Medical Office, Carpentras, France.

Nathalie Bonardel (N)

Médicale Victor Hugo, Avignon, France.

Mireille Dron-Gonzalvez (M)

Medical Office, Martigues, France.

Benoît Sterling (B)

Medical Office, Marseille, France.
Aix-Marseille Univ, APHM, Hôpital Timone, Service de Pneumo-Pédiatrie, Marseille, France.

Ania Carsin (A)

Aix-Marseille Univ, APHM, Hôpital Timone, Service de Pneumo-Pédiatrie, Marseille, France.

Serge Vivinus (S)

Service de Pneumologie, Hôpital Pasteur, CHU Nice, Nice, France.

Bernard Poitevin (B)

Medical Office, Bormes-les-Mimosas, France.

Laureline Nicolau (L)

Medical Office, Perpignan, France.

Geneviève Liautard (G)

Medical Office, Solliès-Pont, France.

Christophe Soler (C)

Laboratoire Synlab Provence, Marseille, France.

Soraya Mezouar (S)

Aix-Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France.

Isabella Annesi-Maesano (I)

Sorbonne Universités, INSERM UMRS 1136, IPLESP, team EPAR, Paris, France.

Jean-Louis Mège (JL)

Aix-Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France.

Jonas Lidholm (J)

Thermo Fisher Scientific, Uppsala, Sweden.

Joana Vitte (J)

Aix-Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH